SIMULTANEOUS RELEASE OF BIOACTIVE AFLIBERCEPT AND DEXAMETHASONE FROM A MICROSPHERE- AND NANOPARTICLE-HYDROGEL OCULAR DRUG DELIVERY SYSTEM FOR THE ENHANCED TREATMENT OF NON-RESPONSIVE PATIENTS WITH CHOROIDAL NEOVASCULARIZATION

Access to IIT electronic theses and dissertations is restricted to IIT community members with a valid iit.edu email address. Please log in using your iit.edu email address and password. Requests for external users are handled through inter-library loan and can be emailed to iitmyillms@iit.edu.

Description

There is a growing subset of wet age-related macular degeneration (AMD) patients who do not fully respond to standard of care treatment, which consists of bimonthly/monthly bolus intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs). Some of these patients may respond... Show moreThere is a growing subset of wet age-related macular degeneration (AMD) patients who do not fully respond to standard of care treatment, which consists of bimonthly/monthly bolus intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs). Some of these patients may respond to a combination therapy of anti-VEGF and corticosteroids. One treatment option uses a dexamethasone implant that releases for six months. This regimen, however, requires both the bimonthly/monthly intravitreal injections of anti-VEGF and semiannual intravitreal injections of the dexamethasone implant. Combining the two treatments into a single drug delivery system (DDS) would reduce the total number of injections, reducing the risk of potential complications (endophthalmitis, retinal detachment, intravitreal hemorrhage, increased intraocular pressure, and cataract) as well as the socioeconomic burden of treatment.The overarching goal of this study was to develop a single DDS that simultaneously releases anti-VEGF (aflibercept) and corticosteroid (dexamethasone) for the treatment of non-responsive wet AMD patients. Our laboratory previously developed a thermoresponsive, biodegradable microparticle-hydrogel DDS that releases anti-VEGF over a period of six months. The aims of the study were to (1) modify this system to include dexamethasone-loaded nanoparticles, optimize release kinetics for both drugs, and characterize the DDS; (2) evaluate the in vivo treatment efficacy in a laser-induced choroidal neovascularization (CNV) model; and (3) investigate the impacts of temperature and storage on the DDS integrity. Show less

Details
Department

BME / Biomedical Engineering

Title

SIMULTANEOUS RELEASE OF BIOACTIVE AFLIBERCEPT AND DEXAMETHASONE FROM A MICROSPHERE- AND NANOPARTICLE-HYDROGEL OCULAR DRUG DELIVERY SYSTEM FOR THE ENHANCED TREATMENT OF NON-RESPONSIVE PATIENTS WITH CHOROIDAL NEOVASCULARIZATION

Institution

Illinois Institute of Technology

Creator(s)

Rudeen, Kayla M

Advisor(s)

Kang-Mieler, Jennifer J

Date

2022

Description

There is a growing subset of wet age-related macular degeneration (AMD) patients who do not fully respond to standard of care treatment, which consists of bimonthly/monthly bolus intravitreal... Show moreThere is a growing subset of wet age-related macular degeneration (AMD) patients who do not fully respond to standard of care treatment, which consists of bimonthly/monthly bolus intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs). Some of these patients may respond to a combination therapy of anti-VEGF and corticosteroids. One treatment option uses a dexamethasone implant that releases for six months. This regimen, however, requires both the bimonthly/monthly intravitreal injections of anti-VEGF and semiannual intravitreal injections of the dexamethasone implant. Combining the two treatments into a single drug delivery system (DDS) would reduce the total number of injections, reducing the risk of potential complications (endophthalmitis, retinal detachment, intravitreal hemorrhage, increased intraocular pressure, and cataract) as well as the socioeconomic burden of treatment.The overarching goal of this study was to develop a single DDS that simultaneously releases anti-VEGF (aflibercept) and corticosteroid (dexamethasone) for the treatment of non-responsive wet AMD patients. Our laboratory previously developed a thermoresponsive, biodegradable microparticle-hydrogel DDS that releases anti-VEGF over a period of six months. The aims of the study were to (1) modify this system to include dexamethasone-loaded nanoparticles, optimize release kinetics for both drugs, and characterize the DDS; (2) evaluate the in vivo treatment efficacy in a laser-induced choroidal neovascularization (CNV) model; and (3) investigate the impacts of temperature and storage on the DDS integrity. Show less

Type

Dissertation

File type

application/pdf

Subject

Biomedical engineering
anti-VEGF
combination release
corticosteroid
drug delivery
neovascularization
ocular

Access

Restricted Access

Rights

In Copyright
http://rightsstatements.org/page/InC/1.0/

Identifier

http://hdl.handle.net/10560/islandora:1024938

<p></p><p></p>